A5084039929- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Sarcoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Esophageal Cancer Research and Treatment
- Retinoids in leukemia and cellular processes
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Phagocytosis and Immune Regulation
- Monoclonal and Polyclonal Antibodies Research
- Hedgehog Signaling Pathway Studies
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Cell Adhesion Molecules Research
- HER2/EGFR in Cancer Research
- Glycosylation and Glycoproteins Research
University Cancer Center Hamburg
2016-2025
University Medical Center Hamburg-Eppendorf
2016-2025
Universität Hamburg
2016-2025
Irepa Laser (France)
2021
Concord Hospital
2019
Samodzielny Publiczny Centralny Szpital Kliniczny
2019
The University of Sydney
2019
Eppendorf (Germany)
1991-2017
Klinikum Bremen-Mitte
2016
Asklepios Klinik St. Georg
2016
All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies treatment arsenic trioxide or without ATRA have shown high efficacy and reduced hematologic toxicity.We conducted a phase 3, multicenter trial comparing plus patients APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either induction consolidation...
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study evaluated the safety and preliminary efficacy of venetoclax, a selective B-cell leukemia/lymphoma-2 inhibitor, together low-dose cytarabine (LDAC) in older adults AML.Adults 60 years or previously untreated AML ineligible chemotherapy were enrolled. Prior myelodysplastic syndrome, including hypomethylating agents (HMA), was...
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. 100 mg (oral, QD) was administered continuously 28-day cycles; LDAC 20 (subcutaneous, BID) 10 per 28 days. Patients (stratified by cytogenetic risk) were randomized (2:1)...
To study the incidence and prognostic impact of mutations in DNA methyltransferase 3A (DNMT3A) patients with acute myeloid leukemia.A total 489 AML were examined for DNMT3A by direct sequencing. The was evaluated context other clinical markers genetic risk factors (cytogenetic group; NPM1, FLT3, CEBPA, IDH1, IDH2, MLL1, NRAS, WT1, WT1 SNPrs16754; expression levels BAALC, ERG, EVI1, MLL5, MN1, WT1).DNMT3A found 87 (17.8%) who younger than 60 years age. Patients older, had higher WBC platelet...
Purpose The initial results of the APL0406 trial showed that combination all- trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA chemotherapy (CHT) in first-line therapy low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report final analysis on complete series patients enrolled onto this trial. Patients Methods study was a prospective, randomized, multicenter, open-label, phase III noninferiority Eligible were adults between...
Acute myeloid leukemia (AML) is a severe and often fatal systemic malignancy. Malignant cells are capable of escaping host immune surveillance by inactivating cytotoxic lymphoid cells. In this work we discovered fundamental molecular pathway, which includes ligand-dependent activation ectopically expressed latrophilin 1 possibly other G-protein coupled receptors leading to increased translation exocytosis the receptor Tim-3 its ligand galectin-9. This occurs in protein kinase C mTOR...
Abstract Purpose: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients Methods: Data were pooled from enrolled in a phase III study (NCT02993523) that compared treated or placebo prior Ib (NCT02203773) where azacitidine. Enrolled ineligible for intensive therapy due to age ≥75 years and/or comorbidities. on received 400 mg orally (days 1–28) (75 mg/m2; days 1–7/28-day cycle). Results: In the...
Abstract Venetoclax‐azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible intensive chemotherapy based on the interim overall survival (OS) analysis VIALE‐A study (NCT02993523). Here, long‐term follow‐up presented to address benefit and outcomes venetoclax‐azacitidine. Patients AML who were randomized 2:1 receive venetoclax‐azacitidine or placebo‐azacitidine. OS was primary endpoint; complete remission with/without blood count recovery...
ABSTRACT This study aimed to evaluate the impact of myelodysplasia‐related gene (MRG) as well additional mutations on outcomes in intensively treated patients with NPM1 ‐mutated ( mut ) AML. Targeted DNA sequencing 263 genes was performed 568 AML (median age: 59 years) entered into prospective AMLSG 09‐09 treatment trial. Most commonly co‐mutated were DNMT3A (49.8%), FLT3 ‐TKD (25.9%), PTPN11 (24.8%), NRAS (22.7%), TET2 (21.7%), IDH2 (21.3%), IDH1 (18%), and ‐ITD (17.3%). MRG identified...
We assessed the prognostic impact of IDH1 R132 mutations and a known single nucleotide polymorphism (SNP) located in same exon gene patients with cytogenetically normal acute myeloid leukemia (CN-AML) context other markers.IDH1 four was directly sequenced 275 CN-AML from two subsequent AML multicenter treatment trials 120 healthy volunteers. Moreover, NPM1, FLT3, CEBPA, WT1 were analyzed, mRNA expression quantified.IDH1 found 10.9% patients. SNP rs11554137 12% 11.7% had no on prognosis. In...
We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in phase 1 dose-escalation study six different dosing schedules. The primary endpoint was frequency severity adverse events (AEs). Secondary endpoints included pharmacokinetics, pharmacodynamics,...